Tarsus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
02/05/2025 05:37
Tarsus Pharmaceuticals Inc TARS.OQ reported a quarterly adjusted loss of 64 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.01. The mean expectation of seven analysts for the quarter was for a loss of 73 cents per share. Wall Street expected results to range from -99 cents to -54 cents per share. Revenue rose 183.7% to $78.34 million from a year ago; analysts expected $72.47 million. Tarsus Pharmaceuticals Inc's reported EPS for the quarter was a loss of 64 cents. The company reported a quarterly loss of $25.12 million. Tarsus Pharmaceuticals Inc shares had risen by 1.1% this quarter and lost 6.2% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 20.6% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy." Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is $73.00 This summary was machine generated from LSEG data May 2 at 04:36 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.73 | -0.64 | Beat |
| Dec. 31 2024 | -0.74 | -0.60 | Beat |
| Sep. 30 2024 | -0.97 | -0.61 | Beat |
| Jun. 30 2024 | -0.92 | -0.88 | Beat |
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)